Abelacimab

Monoclonal antibody

—no market stage

Evidence outlook

Studies registered, no market-specific stage

Studies of this drug are registered, but none is matched to a market this site covers, so no stage is set and there is nothing to grade. The registry list shows each study.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (4)
Other / comorbidity
NCT07739888 · Novartis Pharmaceuticals
2027-12-30 – 2030-12-30 · Atrial Fibrillation (AF)
What this study did
NCT05712200 · Anthos Therapeutics, Inc.
2022-12-27 – 2027-12-30 · Atrial Fibrillation (AF)
What this study did
NCT05171075 · Anthos Therapeutics, Inc.
2022-09-27 – 2026-04-10 · Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
What this study did
NCT05171049 · Anthos Therapeutics, Inc.
2022-05-05 – 2026-02-04 · Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
What this study did
Phase 2 (4)
Other / comorbidity
NCT04755283 · Anthos Therapeutics, Inc.
2021-02-02 – 2028-12-29 · Atrial Fibrillation (AF), Stroke
What this study did
NCT04213807 · Anthos Therapeutics, Inc.
2019-12-11 – 2021-03-08 · Atrial Fibrillation
What this study did
NCT03393481 · Novartis Pharmaceuticals
2018-10-03 – 2020-04-17 · Thrombotic Disorders
What this study did
NCT03398434 · Novartis Pharmaceuticals
2018-10-16 – 2020-01-30 · Atrial Fibrillation
What this study did

Competitive landscape

Other Factor XI/XIa (FXI/FXIa) drugs

KN060. Compare all 2 Factor XI/XIa (FXI/FXIa) drugs

1 other tracked programme targets this mechanism.

This drug's own stage for Stroke Prevention in Atrial Fibrillation: Stage not on record. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Abelacimab: this drugStage not on recordMonoclonal antibodyFactor XI/XIa (FXI/FXIa)not yet gradedNo reviewed efficacy summary in this indication
KN060
Phase 1/2(overall)
Monoclonal antibodyFactor XI/XIa (FXI/FXIa)
not yet graded(overall)
No reviewed efficacy summary in this indication
Amrecibart
Phase 1(overall)
Monoclonal antibodyFactor XInot yet gradedNo reviewed efficacy summary in this indication
Milvexian
Phase 1(overall)
Small molecule—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Abelacimab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
Phase 3Atrial Fibrillation (AF)Recruiting
Est. primary completion 2027-12-30 · NCT05712200 · CT.gov ↗
What to watch
2030 (1)
December 2030 (1)
Phase 3Atrial Fibrillation (AF)Not yet recruiting
Est. primary completion 2030-12-30 · NCT07739888 · CT.gov ↗
What to watch

See the full readout calendar ↗